Last reviewed · How we verify

23vPPV+TIV

Jiangsu Province Centers for Disease Control and Prevention · FDA-approved active Biologic

A combined pneumococcal and influenza vaccine that stimulates immune responses against 23 serotypes of Streptococcus pneumoniae and seasonal influenza virus strains.

This is a combined pneumococcal polysaccharide vaccine (23-valent) plus trivalent inactivated influenza vaccine that stimulates immune responses against 23 serotypes of Streptococcus pneumoniae and three influenza virus strains. Used for Prevention of pneumococcal disease caused by 23 serotypes of Streptococcus pneumoniae, Prevention of seasonal influenza.

At a glance

Generic name23vPPV+TIV
SponsorJiangsu Province Centers for Disease Control and Prevention
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

23vPPV+TIV is a bivalent vaccine combining 23-valent pneumococcal polysaccharide vaccine (23vPPV) and trivalent inactivated influenza vaccine (TIV). The pneumococcal component provides protection against 23 serotypes of S. pneumoniae through polysaccharide-based immunity, while the influenza component induces antibody responses against three seasonal influenza strains. This combination vaccine approach allows simultaneous immunization against both pathogens in a single administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: